4,4′-Bis(2-Bromoacetyl)biphenyl CAS 4072-67-7 Daclatasvir Dihydrochloride Intermediate Purity >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of 4,4'-Bis(2-Bromoacetyl)biphenyl (CAS: 4072-67-7) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase 4,4'-Bis(2-Bromoacetyl)biphenyl, Please contact: alvin@ruifuchem.com
| Chemical Name | 4,4'-Bis(2-Bromoacetyl)biphenyl |
| Synonyms | 4,4'-Bis(Bromoacetyl)biphenyl; 1,1'-[1,1'-Biphenyl]-4,4'-diylbis[2-Bromoethan-1-one]; Daclatasvir Impurity 7 |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 4072-67-7 |
| Molecular Formula | C16H12Br2O2 |
| Molecular Weight | 396.07 g/mol |
| Melting Point | 226.0~227.0℃ |
| Density | 1.622±0.06 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6) |
| Brand | Ruifu Chemical |
| Items | Specifications | Results |
| Appearance | Solid | Solid |
| Purity / Analysis Method | >98.0% (HPLC) | 98.5% |
| Infrared Spectrum | Consistent with Structure | Complies |
| 1H NMR Spectrum | Consistent with Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
| Application | Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6) | |
Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
4,4'-Bis(2-Bromoacetyl)biphenyl (CAS: 4072-67-7) is an intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir Dihydrochloride (Daklinza ) is an inhibitor of hepatitis C virus (HCV) NS5A that is useful in the treatment of genotype 3 chronic hepatitis C infection.
On July 24, 2015, the FDA approved the chronic hepatitis C drug (Bristol-Myers Squibb) for marketing.
The FDA approval process of Daklinza (Bristol-Myers Squibb) has undergone twists and turns. It has been once rejected by the FDA, but finally approved in mid-2015. The FDA approved the combination of Daklinza and Sofosbuvir for the treatment of hepatitis C gene type 3 patients.
In fact, as early as before the FDA approval, Daklinza had been approved for marketing in Japan, the European Union and South Korea and other countries. In 2014, Japanese health sector approved the application of Daklinza and Asunaprevir (Sunvepra) for the treatment of genotype 1 infection. The European Union also approved Daclatasvir to be used in combination with other drugs in the treatment of HCV genotypes 1, 2, 3 and 4 in 2014. Daclatasvir is the first NS5A complex inhibitor approved by European Union (EU). When used in combination with other drugs, compared with the treatment combination of interferon and ribavirin which takes 48 weeks, it has a shorter duration of treatment (12 weeks or 24 weeks).
Daclathavir monotherapy is not recommended, the current mainstream protocol is combination therapy of Dacastavir+ Sofosbuvir, which is characterized by good efficacy, higher SVR, small side effects and further shortened treatment cycle than other options.
